Latest On Aclaris Therapeutics, Inc (ACRS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-08 20:31 EST | News | Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-08 07:15 EST | News | Aclaris Therapeutics GAAP EPS of -$0.42 beats by $0.02, revenue of $2.53M beats by $0.78M | N/A | |
| 2023-05-05 23:32 EST | News | Aclaris Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-03-09 12:31 EST | News | Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa | N/A | |
| 2023-03-06 10:16 EST | News | Aclaris stock falls ~35% as zunsemetinib fails mid-stage study in skin disorder | N/A | |
| 2023-02-23 11:16 EST | News | Aclaris Therapeutics GAAP EPS of -$0.41 beats by $0.05, revenue of $7.75M beats by $5.76M | N/A | |
| 2023-01-12 19:02 EST | News | Aclaris Therapeutics (ACRS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow | N/A | |
| 2023-01-10 19:15 EST | News | Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower | N/A | |
| 2022-12-02 00:46 EST | News | Goldman Sachs initiates Aclaris at Buy citing potential in lead asset | N/A | |
| 2022-11-23 08:47 EST | News | Aclaris Therapeutics names CEO as board chair, COO to take helm | N/A | |
| 2022-10-06 22:31 EST | News | Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions | N/A | |
| 2022-08-26 00:31 EST | News | Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata | N/A | |
| 2022-08-03 16:47 EST | News | Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.05, revenue of $1.53M misses by $0.08M | N/A | |
| 2022-08-01 21:32 EST | News | Aclaris Therapeutics gets a new COO | N/A | |
| 2022-06-27 23:02 EST | News | Aclaris Therapeutics appoints Gail Cawkwell as Chief Medical Officer | N/A | |
| 2022-05-10 22:48 EST | News | Aclaris Therapeutics GAAP EPS of -$0.31 beats by $0.09, revenue of $1.45M misses by $0.22M | N/A | |
| 2022-02-24 08:00 EST | News | Aclaris Therapeutics GAAP EPS of -$0.37 misses by $0.01, revenue of $1.5M misses by $0.3M | N/A | |
| 2022-02-23 12:00 EST | News | Aclaris Therapeutics Q4 2021 Earnings Preview | N/A | |
| 2022-02-01 22:01 EST | News | Aclaris Therapeutics appoints chief business officer | N/A | |
| 2022-01-12 00:16 EST | News | Aclaris falls on the exit of medical chief | N/A | |
| 2021-11-02 11:16 EST | News | Aclaris Therapeutics EPS misses by $0.07, misses on revenue | N/A | |
| 2021-10-02 05:32 EST | News | Aclaris Therapeutics (ACRS) Investor Presentation - Slideshow | N/A | |
| 2021-09-17 12:18 EST | News | Aclaris Therapeutics (ACRS) Presents At 23rd Annual Global Investment Virtual Conference - Slideshow | N/A | |
| 2021-08-27 23:16 EST | News | Aclaris announces proposed settlement of shareholder derivative action | N/A | |
| 2021-08-05 21:07 EST | News | Aclaris Therapeutics EPS misses by $0.06, beats on revenue | N/A | |
| 2021-07-24 07:16 EST | News | Aclaris price target raised at Jefferies citing ‘significant stock moving event’ | N/A | |
| 2021-07-20 17:52 EST | News | Aclaris Therapeutics posts promising data from mid-stage atopic dermatitis trial | N/A | |
| 2021-07-20 17:51 EST | News | Aclaris Therapeutics to raise $75M in stock offering | N/A | |
| 2021-07-20 17:51 EST | News | Aclaris to offer $75M in public offering of stock; shares down 16% | N/A | |
| 2021-07-20 17:49 EST | News | Aclaris to meet competition from Incyte in atopic dermatitis | N/A | |
| 2021-07-20 17:49 EST | News | Aclaris Therapeutics secures $125M capital via equity raise | N/A | |
| 2021-05-07 23:03 EST | News | Aclaris Therapeutics EPS misses by $0.29, beats on revenue | N/A | |
| 2021-03-16 16:01 EST | News | Aclaris Therapeutics (ACRS) Presents At H.C. Wainwright Global Life Sciences Virtual Conference - Slideshow | N/A | |
| 2021-03-15 16:01 EST | News | Aclaris completes enrollment of mid-stage trial for atopic dermatitis | N/A | |
| 2021-03-05 15:01 EST | Analyst Rating | The Analyst Target Price has increased from $25 to $26.67. | Buy | |
| 2021-03-03 02:01 EST | News | Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon | N/A | |
| 2021-02-26 15:01 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-26 03:01 EST | Earnings Estimate | An EPS average of -$1.04 is estimated for the 2022 year. | Sell | |
| 2021-02-26 03:01 EST | Earnings Estimate | An EPS average of -$0.28 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-25 18:35 EST | News | Aclaris Therapeutics EPS misses by $0.04, beats on revenue | N/A | |
| 2021-02-22 16:16 EST | News | Aclaris Therapeutics stock spikes after speculation of potential sale (update) | N/A | |
| 2021-02-02 11:01 EST | Analyst Rating | The Analyst Target Price has increased from $20 to $25. | Buy | |
| 2021-01-21 11:01 EST | Analyst Rating | The Analyst Target Price has increased from $14 to $20. | Buy | |
| 2021-01-20 13:32 EST | News | Aclaris shares rise 10% after pricing equity offering | N/A | |
| 2021-01-20 11:01 EST | Analyst Rating | The Analyst Target Price has increased from $5.83 to $14. | Neutral | |
| 2021-01-19 23:31 EST | News | Aclaris Therapeutics readies proposed public offering | N/A | |
| 2021-01-19 08:31 EST | News | Aclaris stock surges on positive data from mid-stage rheumatoid arthritis ATI-450 trial | N/A | |
| 2021-01-16 11:00 EST | News | Stocks To Watch: Earnings Day For Netflix, Intel And Procter & Gamble | N/A | |
| 2020-12-22 11:01 EST | Analyst Rating | The Analyst Target Price has increased from $5.5 to $5.83. | Neutral | |
| 2020-12-17 11:01 EST | Analyst Rating | The Analyst Target Price has increased from $4.83 to $5.5. | Buy | |
About Aclaris Therapeutics, Inc (ACRS):
Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound that is in phase 2 clinical trial for the treatment of moderate to severe rheumatoid arthritis, COVID-19, and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is in phase 2a clinical trial to treat moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound for the treatment for psoriasis and/or inflammatory bowel disease, as well as A-101 45% topical solution to treat common warts. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
General
- Name Aclaris Therapeutics, Inc
- Symbol ACRS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 57
- Fiscal Year EndDecember
- IPO Date2015-10-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.aclaristx.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 156.98
- Price/Book (Most Recent Quarter) 32.91
- Enterprise Value Revenue 184.55
- Enterprise Value EBITDA 0.05
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.05
- Next Year EPS Estimate -$1.38
- Operating Margin -749%
- Return on Assets -36%
- Return on Equity -95%
- Revenue 6.48 million
- Earnings Per Share -$4.17
- Revenue Per Share $0.15
- Gross Profit -27989000
- Quarterly Earnings Growth 44.3%
View More
Highlights
- Market Capitalization 1.29 billion
- EBITDA -134348000
- PE Ratio -0.99
- PEG Ratio -0.13
- Analyst Target Price $26.67
- Book Value Per Share $0.84
View More
Share Statistics
- Shares Outstanding 51.8 million
- Shares Float 35.44 million
- % Held by Insiders 964%
- % Held by Institutions 66.13%
- Shares Short 758989
- Shares Short Prior Month 1.45 million
- Short Ratio 0.72
- Short % of Float 2%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 0.66
- 52 Week High $26.5
- 52 Week Low $0.85
- 50 Day Moving Average 22.3
- 200 Day Moving Average 9.26
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Aclaris Therapeutics, Inc (ACRS) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Aclaris Therapeutics, Inc (ACRS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $1.58 million | -$0.30 | -$0.26 | -15.38% |
| 2020-09-30 | 2020-11-04 | $1.45 million | -$0.25 | -$0.31 | 18.03% |
| 2020-06-30 | 2020-08-07 | $N/A | -$0.28 | -$0.36 | 21.13% |
| 2020-03-31 | 2020-05-07 | $1.41 million | -$0.37 | -$0.38 | 1.33% |
| 2019-12-31 | 2020-02-25 | $1.1 million | -$0.45 | -$0.39 | -16.37% |
| 2019-09-30 | 2019-11-07 | $983000 | -$1.34 | -$0.69 | -94.2% |
| 2019-06-30 | 2019-08-08 | $5.87 million | -$1.21 | -$0.75 | -62.2% |
| 2019-03-31 | 2019-05-08 | $5.04 million | -$0.91 | -$0.80 | -13.4% |
| 2018-12-31 | 2019-03-18 | $3.67 million | -$0.99 | -$0.98 | -0.68% |
| 2018-09-30 | 2018-11-06 | $1.63 million | -$1.06 | -$1.33 | 20.1% |
| 2018-06-30 | 2018-08-03 | $3.68 million | -$1.01 | -$1.09 | 7.62% |
| 2018-03-31 | 2018-05-08 | $1.12 million | -$0.98 | -$1.00 | 2.32% |
| 2017-12-31 | 2018-03-12 | $999000 | -$0.74 | -$0.88 | 15.91% |
| 2017-09-30 | 2017-11-07 | $684000 | -$0.63 | -$0.87 | 27.59% |
| 2017-06-30 | 2017-08-08 | $N/A | -$0.56 | -$0.73 | 23.29% |
| 2017-03-31 | 2017-05-09 | $N/A | -$0.48 | -$0.59 | 18.64% |
| 2016-12-31 | 2017-03-15 | $N/A | -$0.49 | -$0.64 | 22.83% |
| 2016-09-30 | 2016-11-03 | $N/A | -$0.50 | -$0.67 | 25.65% |
| 2016-06-30 | 2016-08-11 | $N/A | -$0.62 | -$0.65 | 4.13% |
| 2016-03-31 | 2016-05-11 | $N/A | -$0.65 | -$0.50 | -30% |
| 2015-12-31 | 2016-03-23 | $N/A | -$0.28 | -$0.45 | 37.78% |
| 2015-09-30 | 2015-10-13 | $N/A | -$5.11 | -$2.84 | -79.93% |
Aclaris Therapeutics, Inc (ACRS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 8.96 million | 6.87 million | N/A | 9.44 million | 64.9 million |
| Income Before Tax | -13.78 million | -10.66 million | N/A | -15.33 million | -19.45 million |
| Selling General Administrative | 4.9 million | 3.86 million | N/A | 6.2 million | 6.61 million |
| Gross Profit | 294000 | 260000 | N/A | 138000 | 52.36 million |
| Ebit | -13.78 million | -9.87 million | N/A | -14.93 million | -19.14 million |
| Operating Income | -13.56 million | -10.47 million | N/A | -15.51 million | -19.14 million |
| Income Tax Expense | -182000 | N/A | N/A | N/A | N/A |
| Total Revenue | 1.58 million | 1.45 million | N/A | 1.41 million | 1.1 million |
| Cost of Revenue | 1.29 million | 1.19 million | N/A | 1.27 million | -51.27 million |
| Total Other Income Expense Net | N/A | -194000 | N/A | 178000 | -305000 |
| Net Income From Continuing Operations | -13.6 million | -10.66 million | N/A | -15.33 million | -19.45 million |
| Net Income Applicable to Common Shares | -13.17 million | N/A | -11.6 million | -15.59 million | -18.59 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | 5.24 million | -10.49 million | N/A | 22.52 million | N/A |
| Change to Liabilities | N/A | N/A | -4.32 million | -6.21 million | N/A |
| Total Cash Flow from Investing Activities | N/A | N/A | 13.94 million | 56.44 million | N/A |
| Net Borrowings | N/A | N/A | 10.89 million | -30.13 million | N/A |
| Total Cash Flow from Financial Activities | -278000 | -97000 | N/A | -30.01 million | N/A |
| Change to Operating Activities | N/A | N/A | 2.57 million | -9.43 million | N/A |
| Change in Cash | -7.19 million | -21.41 million | N/A | 6.04 million | N/A |
| Total Cash from Operating Activities | -12.15 million | -10.82 million | -6.81 million | -20.39 million | N/A |
| Depreciation | 591000 | 606000 | N/A | 5.05 million | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | 3000 | N/A |
| Change to Account Receivables | -112000 | 158000 | N/A | 12.19 million | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | N/A | 5.22 million | -3.4 million | N/A |
| Capital Expenditures | 304000 | 17000 | N/A | 266000 | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 33.13 million | 31.15 million | 35.63 million | 38.64 million | 28.39 million |
| Total Stockholder Equity | 37.65 million | 40.76 million | 49.37 million | 58.18 million | 69.91 million |
| Other Current Liabilities | 3.71 million | 3.3 million | 2.29 million | 2.66 million | 4.16 million |
| Total Assets | 70.78 million | 71.9 million | 85 million | 96.81 million | 98.3 million |
| Common Stock | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | 2.59 million | 1.75 million | N/A | N/A | 4.97 million |
| Retained Earnings | -504.54 million | -491.37 million | -480.71 million | -469.11 million | -453.53 million |
| Other Liabilities | N/A | 7.74 million | N/A | 4.06 million | 5.95 million |
| Other Assets | N/A | 4.84 million | N/A | 151000 | 4.83 million |
| Cash | 22.06 million | 23.64 million | 32.59 million | 53.99 million | 35.94 million |
| Total Current Liabilities | 14.87 million | 12.79 million | 17.75 million | 20.6 million | 22.43 million |
| Other Stockholder Equity | -94000 | -44000 | N/A | 47000 | -66000 |
| Property, Plant & Equipment | 1.65 million | 1.92 million | N/A | 6.77 million | 2.47 million |
| Total Current Assets | 57.49 million | 58 million | 70.96 million | 82.71 million | 83.8 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 30.53 million | 33.62 million | 51 million | 51 million | 62.71 million |
| Short Term Investments | 32.07 million | 29.83 million | 35.53 million | 25.01 million | 39.08 million |
| Long Term Debt | 10.65 million | 10.61 million | 10.57 million | 10.57 million | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 11.16 million | 5.08 million | 5.5 million | 6.95 million | 9.92 million |
Aclaris Therapeutics, Inc (ACRS) Chart:
Aclaris Therapeutics, Inc (ACRS) News:
Below you will find a list of latest news for Aclaris Therapeutics, Inc (ACRS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Aclaris Therapeutics, Inc (ACRS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 0.5 | 0.76 | CALL | 0 | 28 | 531.15 | TRUE | 0 | 0 |
| 2024-05-17 | 1 | 0.25 | CALL | 10 | 2085 | 56.86 | TRUE | 0 | 0 |
| 2024-05-17 | 1.5 | 0.05 | CALL | 31 | 269 | 96.57 | FALSE | 0.05 | 0 |
| 2024-05-17 | 2 | 0.05 | CALL | 0 | 392 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 3 | 0.05 | CALL | 0 | 30 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 4 | 3.4 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.1 | CALL | 0 | 7 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 6 | 0.05 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7 | 0.03 | CALL | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 8 | 0.1 | CALL | 0 | 73 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 9 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 2.2 | CALL | 0 | 35 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 11 | 1.5 | CALL | 0 | 7 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12 | 0.05 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 13 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 14 | 1.57 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 15 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 16 | 0.05 | CALL | 0 | 9 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 0.5 | 0.05 | PUT | 0 | 11 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 1 | 0.05 | PUT | 5 | 505 | 115.64 | FALSE | 0.05 | 0 |
| 2024-05-17 | 1.5 | 0.35 | PUT | 0 | 356 | 91.98 | TRUE | 0 | 0 |
| 2024-05-17 | 2 | 1 | PUT | 0 | 7 | 362.09 | TRUE | 0 | 0 |
| 2024-05-17 | 3 | 2.1 | PUT | 0 | 0 | 624.22 | TRUE | 0 | 0 |
| 2024-05-17 | 4 | 3.02 | PUT | 0 | 0 | 435.02 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 3.41 | PUT | 0 | 0 | 434.01 | TRUE | 0 | 0 |
| 2024-05-17 | 6 | 4.9 | PUT | 0 | 0 | 466.08 | TRUE | 0 | 0 |
| 2024-05-17 | 7 | 0 | PUT | 0 | 0 | 492.52 | TRUE | 0 | 0 |
| 2024-05-17 | 8 | 0 | PUT | 0 | 0 | 638 | TRUE | 0 | 0 |
| 2024-05-17 | 9 | 0 | PUT | 0 | 0 | 421.1 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | PUT | 0 | 0 | 825.89 | TRUE | 0 | 0 |
| 2024-05-17 | 11 | 0 | PUT | 0 | 0 | 567.54 | TRUE | 0 | 0 |
| 2024-05-17 | 12 | 8.21 | PUT | 0 | 0 | 743.82 | TRUE | 0 | 0 |
| 2024-05-17 | 13 | 0 | PUT | 0 | 0 | 639.03 | TRUE | 0 | 0 |
| 2024-05-17 | 14 | 0 | PUT | 0 | 0 | 843.96 | TRUE | 0 | 0 |
| 2024-05-17 | 15 | 0 | PUT | 0 | 0 | 742.49 | TRUE | 0 | 0 |
| 2024-05-17 | 16 | 0 | PUT | 0 | 0 | 713.83 | TRUE | 0 | 0 |
| 2024-06-21 | 0.5 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 1 | 0 | CALL | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 1.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 3 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 1.5 | 0 | PUT | 0 | 0 | 115.84 | TRUE | 0 | 0 |
| 2024-06-21 | 2 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-06-21 | 3 | 0 | PUT | 0 | 0 | 500.07 | TRUE | 0 | 0 |
| 2024-06-21 | 4 | 0 | PUT | 0 | 0 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 0.5 | 0.78 | CALL | 0 | 3 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 1 | 0.4 | CALL | 0 | 162 | 0 | TRUE | 0 | 0 |
| 2024-08-16 | 1.5 | 0.22 | CALL | 0 | 69 | 99.9 | FALSE | 0 | 0 |
| 2024-08-16 | 2 | 0.1 | CALL | 0 | 40 | 99.02 | FALSE | 0 | 0 |
| 2024-08-16 | 3 | 0.15 | CALL | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 4 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 0.5 | 0.04 | PUT | 0 | 32 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 1 | 0.2 | PUT | 0 | 8 | 104.13 | FALSE | 0 | 0 |
| 2024-08-16 | 1.5 | 0.66 | PUT | 0 | 2 | 104.32 | TRUE | 0 | 0 |
| 2024-08-16 | 2 | 1.1 | PUT | 0 | 5 | 105.48 | TRUE | 0 | 0 |
| 2024-08-16 | 3 | 0 | PUT | 0 | 0 | 138.38 | TRUE | 0 | 0 |
| 2024-08-16 | 4 | 0 | PUT | 0 | 0 | 388.31 | TRUE | 0 | 0 |
| 2024-11-15 | 0.5 | 0.84 | CALL | 0 | 115 | 0 | TRUE | 0 | 0 |
| 2024-11-15 | 1 | 0.5 | CALL | 10 | 191 | 107.86 | TRUE | 0 | 0 |
| 2024-11-15 | 1.5 | 0.28 | CALL | 0 | 96 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2 | 0.17 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 3 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 4 | 0.45 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 0.5 | 0.1 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 1 | 0 | PUT | 0 | 0 | 88.47 | FALSE | 0 | 0 |
| 2024-11-15 | 1.5 | 0.6 | PUT | 0 | 0 | 94.65 | TRUE | 0 | 0 |
| 2024-11-15 | 2 | 0 | PUT | 0 | 0 | 97.9 | TRUE | 0 | 0 |
| 2024-11-15 | 3 | 0 | PUT | 0 | 0 | 100.66 | TRUE | 0 | 0 |
| 2024-11-15 | 4 | 0 | PUT | 0 | 0 | 123.18 | TRUE | 0 | 0 |
Latest ACRS Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 80 | $12.925 |
| Jun 13, 2022 7:59 PM EST | 22 | $12.935 |
| Jun 13, 2022 7:59 PM EST | 19 | $12.93 |
| Jun 13, 2022 7:59 PM EST | 24 | $12.93 |
| Jun 13, 2022 7:59 PM EST | 5 | $12.93 |
Aclaris Therapeutics, Inc (ACRS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000090266420002531/0000902664-20-002531-index.htm |
| 2020-03-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1557746/000000000020002443/0000000000-20-002443-index.htm |
| 2019-01-25 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000003877719000005/0000038777-19-000005-index.htm |
| 2020-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000003877720000013/0000038777-20-000013-index.htm |
| 2019-02-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000021545719003192/0000215457-19-003192-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000031506619000849/0000315066-19-000849-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000031506620000819/0000315066-20-000819-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000083423720004757/0000834237-20-004757-index.htm |
| 2020-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000083423720009989/0000834237-20-009989-index.htm |
| 2019-08-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000089542119000589/0000895421-19-000589-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000089542120000139/0000895421-20-000139-index.htm |
| 2020-03-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000089542120000278/0000895421-20-000278-index.htm |
| 2020-06-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000090266420002531/0000902664-20-002531-index.htm |
| 2019-10-31 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000090445419000691/0000904454-19-000691-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000090445420000171/0000904454-20-000171-index.htm |
| 2020-07-22 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000090445420000503/0000904454-20-000503-index.htm |
| 2019-07-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000090514819000691/0000905148-19-000691-index.htm |
| 2020-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000090514820000306/0000905148-20-000306-index.htm |
| 2019-01-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000091957419000663/0000919574-19-000663-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000091957420001125/0000919574-20-001125-index.htm |
| 2019-10-15 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1557746/000092189519002554/0000921895-19-002554-index.htm |
| 2019-11-21 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1557746/000092189519002853/0000921895-19-002853-index.htm |
| 2019-12-19 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1557746/000092189519003037/0000921895-19-003037-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000093583620000140/0000935836-20-000140-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000103738920000090/0001037389-20-000090-index.htm |
| 2019-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000110465919049176/0001104659-19-049176-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000110465920021847/0001104659-20-021847-index.htm |
| 2020-03-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000110465920030172/0001104659-20-030172-index.htm |
| 2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000110465920033094/0001104659-20-033094-index.htm |
| 2020-03-13 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1557746/000110465920033140/0001104659-20-033140-index.htm |
| 2020-04-23 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1557746/000110465920050082/0001104659-20-050082-index.htm |
| 2020-04-29 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1557746/000110465920053341/0001104659-20-053341-index.htm |
| 2020-08-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1557746/000110465920094778/0001104659-20-094778-index.htm |
| 2020-08-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000110465920094781/0001104659-20-094781-index.htm |
| 2020-10-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000110465920118249/0001104659-20-118249-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000114420419008093/0001144204-19-008093-index.htm |
| 2019-07-29 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000117266119001597/0001172661-19-001597-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000117266120000734/0001172661-20-000734-index.htm |
| 2020-10-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000117266120002035/0001172661-20-002035-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000119380518001435/0001193805-18-001435-index.htm |
| 2018-12-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000119380518001441/0001193805-18-001441-index.htm |
| 2019-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000014/0001193805-19-000014-index.htm |
| 2019-01-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000067/0001193805-19-000067-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000181/0001193805-19-000181-index.htm |
| 2019-05-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000485/0001193805-19-000485-index.htm |
| 2019-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000599/0001193805-19-000599-index.htm |
| 2019-06-26 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000603/0001193805-19-000603-index.htm |
| 2019-07-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000616/0001193805-19-000616-index.htm |
| 2019-07-31 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000689/0001193805-19-000689-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1557746/000119380520000193/0001193805-20-000193-index.htm |
| 2018-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063368/0001209191-18-063368-index.htm |
| 2018-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063369/0001209191-18-063369-index.htm |
| 2018-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063370/0001209191-18-063370-index.htm |
| 2018-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063372/0001209191-18-063372-index.htm |
| 2018-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063373/0001209191-18-063373-index.htm |
| 2018-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063795/0001209191-18-063795-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063801/0001209191-18-063801-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063802/0001209191-18-063802-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063803/0001209191-18-063803-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063804/0001209191-18-063804-index.htm |
| 2018-12-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063805/0001209191-18-063805-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007485/0001209191-19-007485-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007486/0001209191-19-007486-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007487/0001209191-19-007487-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007488/0001209191-19-007488-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007489/0001209191-19-007489-index.htm |
| 2019-02-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007490/0001209191-19-007490-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119015882/0001209191-19-015882-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119015888/0001209191-19-015888-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119015892/0001209191-19-015892-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119015894/0001209191-19-015894-index.htm |
| 2019-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119015898/0001209191-19-015898-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119035829/0001209191-19-035829-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119035830/0001209191-19-035830-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119035832/0001209191-19-035832-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119035835/0001209191-19-035835-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119035840/0001209191-19-035840-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119035916/0001209191-19-035916-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119041173/0001209191-19-041173-index.htm |
| 2019-07-03 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119041174/0001209191-19-041174-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119041175/0001209191-19-041175-index.htm |
| 2019-10-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119054623/0001209191-19-054623-index.htm |
| 2019-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061067/0001209191-19-061067-index.htm |
| 2019-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061068/0001209191-19-061068-index.htm |
| 2019-12-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061069/0001209191-19-061069-index.htm |
| 2019-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061536/0001209191-19-061536-index.htm |
| 2019-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061540/0001209191-19-061540-index.htm |
| 2019-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061545/0001209191-19-061545-index.htm |
| 2020-01-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120002761/0001209191-20-002761-index.htm |
| 2020-01-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120002767/0001209191-20-002767-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120006666/0001209191-20-006666-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120006667/0001209191-20-006667-index.htm |
| 2020-02-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120006668/0001209191-20-006668-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016065/0001209191-20-016065-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016073/0001209191-20-016073-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016076/0001209191-20-016076-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016078/0001209191-20-016078-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016081/0001209191-20-016081-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016084/0001209191-20-016084-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016086/0001209191-20-016086-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016088/0001209191-20-016088-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016090/0001209191-20-016090-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016092/0001209191-20-016092-index.htm |
| 2020-03-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016095/0001209191-20-016095-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120034060/0001209191-20-034060-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120034065/0001209191-20-034065-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120034068/0001209191-20-034068-index.htm |
| 2020-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120034076/0001209191-20-034076-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035025/0001209191-20-035025-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035029/0001209191-20-035029-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035031/0001209191-20-035031-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035032/0001209191-20-035032-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035033/0001209191-20-035033-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035034/0001209191-20-035034-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035056/0001209191-20-035056-index.htm |
| 2020-06-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035059/0001209191-20-035059-index.htm |
| 2020-07-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120041565/0001209191-20-041565-index.htm |
| 2020-09-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1557746/000120919120049398/0001209191-20-049398-index.htm |
| 2020-04-08 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1557746/000123191920000022/0001231919-20-000022-index.htm |
| 2018-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837018009771/0001558370-18-009771-index.htm |
| 2019-01-18 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019000179/0001558370-19-000179-index.htm |
| 2019-02-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019000521/0001558370-19-000521-index.htm |
| 2019-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019002208/0001558370-19-002208-index.htm |
| 2019-03-18 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1557746/000155837019002211/0001558370-19-002211-index.htm |
| 2019-03-29 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1557746/000155837019002649/0001558370-19-002649-index.htm |
| 2019-04-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019002790/0001558370-19-002790-index.htm |
| 2019-04-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1557746/000155837019003262/0001558370-19-003262-index.htm |
| 2019-04-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1557746/000155837019003265/0001558370-19-003265-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019004465/0001558370-19-004465-index.htm |
| 2019-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1557746/000155837019004494/0001558370-19-004494-index.htm |
| 2019-06-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019005495/0001558370-19-005495-index.htm |
| 2019-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019005542/0001558370-19-005542-index.htm |
| 2019-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019005736/0001558370-19-005736-index.htm |
| 2019-07-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019006015/0001558370-19-006015-index.htm |
| 2019-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019006557/0001558370-19-006557-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019007711/0001558370-19-007711-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1557746/000155837019007745/0001558370-19-007745-index.htm |
| 2019-09-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019008497/0001558370-19-008497-index.htm |
| 2019-09-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019008709/0001558370-19-008709-index.htm |
| 2019-10-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019008878/0001558370-19-008878-index.htm |
| 2019-10-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019008933/0001558370-19-008933-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019010383/0001558370-19-010383-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1557746/000155837019010425/0001558370-19-010425-index.htm |
| 2019-11-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019011167/0001558370-19-011167-index.htm |
| 2019-12-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837019011272/0001558370-19-011272-index.htm |
| 2020-01-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020000075/0001558370-20-000075-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020000132/0001558370-20-000132-index.htm |
| 2020-02-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020001319/0001558370-20-001319-index.htm |
| 2020-02-25 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1557746/000155837020001325/0001558370-20-001325-index.htm |
| 2020-03-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020003444/0001558370-20-003444-index.htm |
| 2020-04-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1557746/000155837020004176/0001558370-20-004176-index.htm |
| 2020-04-23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1557746/000155837020004178/0001558370-20-004178-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020005715/0001558370-20-005715-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1557746/000155837020005744/0001558370-20-005744-index.htm |
| 2020-05-07 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1557746/000155837020005771/0001558370-20-005771-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020006658/0001558370-20-006658-index.htm |
| 2020-05-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020006989/0001558370-20-006989-index.htm |
| 2020-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020007276/0001558370-20-007276-index.htm |
| 2020-06-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020007565/0001558370-20-007565-index.htm |
| 2020-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020007743/0001558370-20-007743-index.htm |
| 2020-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020009808/0001558370-20-009808-index.htm |
| 2020-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1557746/000155837020009814/0001558370-20-009814-index.htm |
| 2020-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020010689/0001558370-20-010689-index.htm |
| 2020-09-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020011154/0001558370-20-011154-index.htm |
| 2020-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1557746/000155837020012486/0001558370-20-012486-index.htm |
| 2020-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1557746/000155837020012488/0001558370-20-012488-index.htm |
| 2019-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1557746/000161577419002509/0001615774-19-002509-index.htm |
| 2020-04-29 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1557746/999999999520000907/9999999995-20-000907-index.htm |
| 2018-12-20 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1557746/999999999718009613/9999999997-18-009613-index.htm |
| 2019-05-09 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1557746/999999999719004164/9999999997-19-004164-index.htm |
Aclaris Therapeutics, Inc (ACRS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aclaris Therapeutics, Inc (ACRS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 964%Institutional Ownership: 6613%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-03-02 | Neal Walker | President and CEO | Buy | 96,150.00 | 1,025,053.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016095/0001209191-20-016095-index.htm | ||
| 2020-03-02 | Kamil Ali-Jackson | Chief Legal Officer | Buy | 17,175.00 | 103,978.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016073/0001209191-20-016073-index.htm | ||
| 2020-03-02 | Neal Walker | President and CEO | Buy | 52,564.00 | 1,049,994.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016095/0001209191-20-016095-index.htm | ||
| 2020-06-01 | David N. Gordon | Chief Medical Officer | Buy | 87,500.00 | 106,940.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120034065/0001209191-20-034065-index.htm | ||
| 2019-06-26 | James E Flynn | 10% Share Holder | Sell | 352.00 | 4.50 | 1,584.53 | 1,072,775.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000603/0001193805-19-000603-index.htm |
| 2019-06-25 | James E Flynn | 10% Share Holder | Sell | 10,634.00 | 4.51 | 47,947.64 | 1,073,127.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000599/0001193805-19-000599-index.htm |
| 2019-06-24 | James E Flynn | 10% Share Holder | Sell | 13,063.00 | 4.52 | 59,077.42 | 1,083,761.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000599/0001193805-19-000599-index.htm |
| 2019-06-21 | James E Flynn | 10% Share Holder | Sell | 70,135.00 | 4.62 | 323,701.08 | 1,096,824.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000599/0001193805-19-000599-index.htm |
| 2020-06-01 | Neal Walker | President and CEO | Buy | 73,014.00 | 1,107,907.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120034076/0001209191-20-034076-index.htm | ||
| 2019-05-10 | James E Flynn | 10% Share Holder | Sell | 71,869.00 | 6.05 | 434,749.95 | 1,166,959.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000485/0001193805-19-000485-index.htm |
| 2020-09-01 | Neal Walker | President and CEO | Buy | 83,092.00 | 1,170,023.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120049398/0001209191-20-049398-index.htm | ||
| 2019-02-01 | Brett Fair | Chief Commercial Officer | Buy | 3,875.00 | 11,890.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007486/0001209191-19-007486-index.htm | ||
| 2019-05-09 | James E Flynn | 10% Share Holder | Sell | 172,800.00 | 6.16 | 1,064,016.00 | 1,238,828.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000485/0001193805-19-000485-index.htm |
| 2020-06-01 | Kamil Ali-Jackson | Chief Legal Officer | Buy | 33,188.00 | 132,387.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120034060/0001209191-20-034060-index.htm | ||
| 2018-12-15 | Christopher Powala | Chief Reg & Develop Officer | Buy | 1,300.00 | 138,621.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063368/0001209191-18-063368-index.htm | ||
| 2018-12-18 | Christopher Powala | Chief Reg & Develop Officer | Buy | 1,625.00 | 139,889.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063801/0001209191-18-063801-index.htm | ||
| 2019-02-01 | Christopher Powala | Chief Reg & Develop Officer | Buy | 3,400.00 | 142,843.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007489/0001209191-19-007489-index.htm | ||
| 2018-12-15 | Frank Ruffo | Chief Financial Officer | Buy | 1,300.00 | 161,885.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063372/0001209191-18-063372-index.htm | ||
| 2020-06-06 | Anand Mehra | Director | Buy | 7,333.00 | 16,209.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035033/0001209191-20-035033-index.htm | ||
| 2020-06-06 | ANDREW N SCHIFF | Director | Buy | 7,333.00 | 16,209.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035029/0001209191-20-035029-index.htm | ||
| 2020-06-06 | Bryan M. Reasons | Director | Buy | 7,333.00 | 16,209.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035059/0001209191-20-035059-index.htm | ||
| 2020-06-06 | William D. Humphries | Director | Buy | 7,333.00 | 16,209.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035032/0001209191-20-035032-index.htm | ||
| 2018-12-18 | Frank Ruffo | Chief Financial Officer | Buy | 1,250.00 | 162,765.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063805/0001209191-18-063805-index.htm | ||
| 2020-03-02 | Christopher P. Molineaux | Director | Buy | 8,876.00 | 16,558.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016084/0001209191-20-016084-index.htm | ||
| 2019-12-16 | Frank Ruffo | Chief Financial Officer | Buy | 1,300.00 | 166,276.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061068/0001209191-19-061068-index.htm | ||
| 2019-02-01 | Frank Ruffo | Chief Financial Officer | Buy | 3,875.00 | 166,284.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007487/0001209191-19-007487-index.htm | ||
| 2020-06-06 | Andrew Kenneth William Powell | Director | Buy | 7,333.00 | 16,709.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035031/0001209191-20-035031-index.htm | ||
| 2019-12-18 | Frank Ruffo | Chief Financial Officer | Buy | 1,250.00 | 167,156.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061540/0001209191-19-061540-index.htm | ||
| 2020-02-03 | Frank Ruffo | Chief Financial Officer | Buy | 3,875.00 | 170,675.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120006667/0001209191-20-006667-index.htm | ||
| 2020-03-02 | Frank Ruffo | Chief Financial Officer | Buy | 25,750.00 | 195,117.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016092/0001209191-20-016092-index.htm | ||
| 2020-06-01 | Frank Ruffo | Chief Financial Officer | Buy | 33,188.00 | 221,143.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120034068/0001209191-20-034068-index.htm | ||
| 2020-06-06 | Christopher P. Molineaux | Director | Buy | 7,333.00 | 23,891.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120035034/0001209191-20-035034-index.htm | ||
| 2020-03-02 | David N. Gordon | Chief Medical Officer | Buy | 20,600.00 | 24,952.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016065/0001209191-20-016065-index.htm | ||
| 2018-12-15 | Stuart Shanler | Chief Scientific Officer | Buy | 1,300.00 | 268,812.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063370/0001209191-18-063370-index.htm | ||
| 2018-12-18 | Stuart Shanler | Chief Scientific Officer | Buy | 1,450.00 | 269,892.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063803/0001209191-18-063803-index.htm | ||
| 2019-02-01 | Stuart Shanler | Chief Scientific Officer | Buy | 3,875.00 | 273,355.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007488/0001209191-19-007488-index.htm | ||
| 2019-06-27 | James E Flynn | 10% Share Holder | Sell | 590,801.00 | 2.69 | 1,589,668.25 | 3,159,165.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000616/0001193805-19-000616-index.htm |
| 2019-06-26 | James E Flynn | 10% Share Holder | Sell | 1,352.00 | 4.50 | 6,086.03 | 3,749,966.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000603/0001193805-19-000603-index.htm |
| 2019-06-25 | James E Flynn | 10% Share Holder | Sell | 40,850.00 | 4.51 | 184,188.57 | 3,751,318.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000599/0001193805-19-000599-index.htm |
| 2019-06-24 | James E Flynn | 10% Share Holder | Sell | 50,177.00 | 4.52 | 226,925.48 | 3,792,168.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000599/0001193805-19-000599-index.htm |
| 2019-06-21 | James E Flynn | 10% Share Holder | Sell | 269,402.00 | 4.62 | 1,243,397.99 | 3,842,345.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000599/0001193805-19-000599-index.htm |
| 2019-05-10 | James E Flynn | 10% Share Holder | Sell | 108,696.00 | 6.05 | 657,523.84 | 4,111,747.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000485/0001193805-19-000485-index.htm |
| 2019-05-09 | James E Flynn | 10% Share Holder | Sell | 261,345.00 | 6.16 | 1,609,231.84 | 4,220,443.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000485/0001193805-19-000485-index.htm |
| 2020-03-02 | MAXINE GOWEN | Director | Buy | 4,438.00 | 4,438.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016076/0001209191-20-016076-index.htm | ||
| 2019-07-02 | David N. Gordon | Chief Medical Officer | Buy | 6,000.00 | 6,000.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119041173/0001209191-19-041173-index.htm | ||
| 2018-12-15 | Kamil Ali-Jackson | Chief Legal Officer | Buy | 1,733.00 | 79,369.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063369/0001209191-18-063369-index.htm | ||
| 2018-12-18 | Kamil Ali-Jackson | Chief Legal Officer | Buy | 1,075.00 | 79,951.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063795/0001209191-18-063795-index.htm | ||
| 2019-02-01 | Kamil Ali-Jackson | Chief Legal Officer | Buy | 3,875.00 | 83,520.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007485/0001209191-19-007485-index.htm | ||
| 2019-12-16 | Kamil Ali-Jackson | Chief Legal Officer | Buy | 1,733.00 | 83,945.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061067/0001209191-19-061067-index.htm | ||
| 2019-12-18 | Kamil Ali-Jackson | Chief Legal Officer | Buy | 1,075.00 | 84,523.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061536/0001209191-19-061536-index.htm | ||
| 2018-12-18 | Brett Fair | Chief Commercial Officer | Buy | 1,750.00 | 8,513.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063802/0001209191-18-063802-index.htm | ||
| 2020-02-03 | Kamil Ali-Jackson | Chief Legal Officer | Buy | 3,875.00 | 88,121.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120006666/0001209191-20-006666-index.htm | ||
| 2020-03-02 | Anand Mehra | Director | Buy | 8,876.00 | 8,876.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016081/0001209191-20-016081-index.htm | ||
| 2020-03-02 | ANDREW N SCHIFF | Director | Buy | 8,876.00 | 8,876.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016090/0001209191-20-016090-index.htm | ||
| 2020-03-02 | Bryan M. Reasons | Director | Buy | 8,876.00 | 8,876.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016088/0001209191-20-016088-index.htm | ||
| 2020-03-02 | William D. Humphries | Director | Buy | 8,876.00 | 8,876.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016078/0001209191-20-016078-index.htm | ||
| 2020-07-02 | David N. Gordon | Chief Medical Officer | Buy | 6,000.00 | 88,895.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120041565/0001209191-20-041565-index.htm | ||
| 2018-12-15 | Neal Walker | President and CEO | Buy | 3,033.00 | 908,895.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063373/0001209191-18-063373-index.htm | ||
| 2018-12-18 | Neal Walker | President and CEO | Buy | 2,925.00 | 910,957.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919118063804/0001209191-18-063804-index.htm | ||
| 2019-12-16 | Neal Walker | President and CEO | Buy | 3,033.00 | 920,378.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061069/0001209191-19-061069-index.htm | ||
| 2019-02-01 | Neal Walker | President and CEO | Buy | 10,800.00 | 920,924.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119007490/0001209191-19-007490-index.htm | ||
| 2019-12-18 | Neal Walker | President and CEO | Buy | 2,925.00 | 922,521.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919119061545/0001209191-19-061545-index.htm | ||
| 2020-02-03 | Neal Walker | President and CEO | Buy | 10,800.00 | 932,578.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120006668/0001209191-20-006668-index.htm | ||
| 2020-03-02 | Andrew Kenneth William Powell | Director | Buy | 8,876.00 | 9,376.00 | https://www.sec.gov/Archives/edgar/data/1557746/000120919120016086/0001209191-20-016086-index.htm | ||
| 2019-06-27 | James E Flynn | 10% Share Holder | Sell | 108,674.00 | 2.69 | 292,409.13 | 964,101.00 | https://www.sec.gov/Archives/edgar/data/1557746/000119380519000616/0001193805-19-000616-index.htm |